[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Zhu et al., 1998 - Google Patents

NMDA-R1 antisense oligonucleotide attenuates withdrawal signs from morphine

Zhu et al., 1998

Document ID
3662543748004945494
Author
Zhu H
Ho K
Publication year
Publication venue
European journal of pharmacology

External Links

Snippet

To test the involvement of NMDA receptor in the development of physical dependence on opioid, the effects of an antisense oligonucleotide against NMDA receptors on the naloxone precipitated withdrawal from morphine were studied. Antisense oligonucleotide (15 nmol/5 …
Continue reading at www.sciencedirect.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epihephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Similar Documents

Publication Publication Date Title
Zhu et al. NMDA-R1 antisense oligonucleotide attenuates withdrawal signs from morphine
Bilsky et al. Competitive and non-competitive NMDA antagonists block the development of antinociceptive tolerance to morphine, but not to selective μ or δ opioid agonists in mice
Crain et al. Acute thermal hyperalgesia elicited by low-dose morphine in normal mice is blocked by ultra-low-dose naltrexone, unmasking potent opioid analgesia
Tokuyama et al. Direct evidence for a role of glutamate in the expression of the opioid withdrawal syndrome
Trujillo Are NMDA receptors involved in opiate-induced neural and behavioral plasticity? A review of preclinical studies
González et al. Decrease of tolerance to, and physical dependence on morphine by glutamate receptor antagonists
Mika et al. The role of δ-opioid receptor subtypes in neuropathic pain
Zhu et al. The role of glutamate in physical dependence on opioids
AU7474194A (en) Methods of enhancing opiate analgesic potency or detoxifying an opiate addict
Panerai et al. Dissociation of tolerance and dependence to morphine: a possible role for cholecystokinin
Zhu et al. Region-specific changes in NMDA receptor mRNA induced by chronic morphine treatment are prevented by the co-administration of the competitive NMDA receptor antagonist LY274614
Zhu et al. Region specific expression of NMDA receptor NR1 subunit mRNA in hypothalamus and pons following chronic morphine treatment
Leal et al. Ibogaine attenuation of morphine withdrawal in mice: role of glutamate N-methyl-D-aspartate receptors
Ramarao et al. Effect of κ-opioid receptor agonists on morphine analgesia in morphine-naive and morphine-tolerant rats
Honar et al. Ultra-low dose naltrexone potentiates the anticonvulsant effect of low dose morphine on clonic seizures
Wen et al. Cholecystokinin octapeptide induces endogenous opioid-dependent anxiolytic effects in morphine-withdrawal rats
Tokuyama et al. Ca2+ channel blocker, diltiazem, prevents physical dependence and the enhancement of protein kinase C activity by opioid infusion in rats
US7256200B2 (en) Method and composition for potentiating an oplate analgesic
Suh et al. Differential effects of sulfated cholecystokinin octapeptide and proglumide injected intrathecally on antinociception induced by β-endorphin and morphine administered intracerebroventricularly in mice
Fraser et al. Supraspinal antinociceptive response to [D-Pen2, 5]-enkephalin (DPDPE) is pharmacologically distinct from that to other δ-agonists in the rat
Pastor et al. Effect of selective antagonism of mu (1)-, mu (1/2)-, mu (3)-, and delta-opioid receptors on the locomotor-stimulating actions of ethanol
Holtman Jr et al. Sex-related differences in the enhancement of morphine antinociception by NMDA receptor antagonists in rats
Tseng 13 Mechanisms of β-Endorphin-Induced Antinociception
Farzin Modification of naloxone-induced withdrawal signs by dextromethorphan in morphine-dependent mice
Zhao et al. Effect of antagonism of the NMDA receptor on tolerance to [D-Pen2, D-Pen5] enkephalin, a δ1-opioid receptor agonist